Zobrazeno 1 - 10 of 18 pro vyhledávání: '"PARAMOUNT trial"'
1
4CPS-073 Effectiveness and safety of platin/permetrexed combination in non-small cell lung cancer
Autor: M Dominguez-Cantero, Silvia Fénix-Caballero, FJ Salmeron-Navas, EM Barreiro Fernandez, C Martinez-Diaz
Publikováno v: Section 4: Clinical Pharmacy Services.
Background and importance According to the PARAMOUNT trial, induction chemotherapy with a platin/pemetrexed combination and pemetrexed maintenance therapy reduced the risk of progression free survival (PFS) and overall survival (OS) in patients with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::153397e0dae1dc8c941d4878ec4c3daa
https://doi.org/10.1136/ejhpharm-2020-eahpconf.174
Zobrazit plný text záznamu
2
4CPS-124 Effectiveness of maintenance therapy with oral vinorelbine for non-small-cell lung cancer
Autor: A Martinez Torron, A. Martínez, C Carriles Fernandez, I Zapico García, A Llorente Romeo, A Lozano-Blázquez, R Jimenez Galan
Publikováno v: Eur J Hosp Pharm
Background Combination of platinum with a third-generation agent, usually vinorelbine, is considered the standard first line in non-small-cell lung cancer (NSCLC). Purpose To analyse overall survival (OS) and progression-free survival (PFS) of mainte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4151a23fa40c2569694f2be10c2a0d99
https://europepmc.org/articles/PMC7535366/
Zobrazit plný text záznamu
3
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Autor: Adriaan A. Voors, Milton Packer, Michael R. Zile, Mauro Gori, Martin Lefkowitz, Brian Claggett, Burkert Pieske, John J.V. McMurray, Victor Shi, Licette C. Y. Liu, Scott D. Solomon
Publikováno v: European Journal of Heart Failure. 17:510-517
Background Increases in serum creatinine with renin–angiotensin–aldosterone system (RAAS) inhibitors can lead to unnecessary discontinuation of these agents. The dual-acting angiotensin receptor neprilysin inhibitor LCZ696 improves clinical outco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dadb96966c032065bff5c16ef60abea
https://doi.org/10.1002/ejhf.232
Zobrazit plný text záznamu
4
Impaired left atrial function in heart failure with preserved ejection fraction
Autor: Scott D. Solomon, Milton Packer, Brian Claggett, Adriaan A. Voors, Victor Shi, Burkert Pieske, Deepak K. Gupta, Amil M. Shah, Michael R. Zile, Marty P. Lefkowitz, Angela B. S. Santos, Elisabeth Kraigher-Krainer, John J.V. McMurray, Toni Bransford
Publikováno v: European Journal of Heart Failure. 16:1096-1103
AimsLeft atrial (LA) enlargement is present in the majority of heart failure with preserved ejection fraction (HFpEF) patients and is a marker of risk. However, the importance of LA function in HFpEF is less well understood. Methods and resultsThe PA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd5f1bf458845d09b6ff437778769d46
https://doi.org/10.1002/ejhf.147
Zobrazit plný text záznamu
6
The PARAMOUNT trial: implications for maintenance therapy in lung cancer patients
Autor: Antonio Rossi
Publikováno v: Lung Cancer Management. 2:243-246
243 ISSN 1758-1966 10.2217/LMT.13.28 © 2013 Future Medicine Ltd Lung Cancer Manage. (2013) 2(4), 243–246 The maintenance strategic approach has been extensively investigated in hematologic malignancies and then in solid tumors. Among thoracic canc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::123b6d1d8fc263550c4da83c61995cee
https://doi.org/10.2217/lmt.13.28
Zobrazit plný text záznamu
7
THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), SACUBITRIL/VALSARTAN, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (PARAMOUNT TRIAL)
Autor: Burkert Pieske, Brian Claggett, Victor Shi, Elisabeth Pieske-Kraigher, Amil M. Shah, Adriaan A. Voors, Michael Zile, Milton Packer, Tor Biering-Sørensen, Martin Lefkowitz, John J.V. McMurray, Scott D. Solomon
Publikováno v: Journal of the American College of Cardiology. 71:A2665
The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) improves cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF), and reduced NT-proBNP and left atrial size in a phase II heart failure with pres
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12d4ff8c7f55440aa73b5a5436680efc
https://doi.org/10.1016/s0735-1097(18)33206-6
Zobrazit plný text záznamu
8
Phase II PARAMOUNT trial of LCZ696
Autor: Bryony M. Mearns
Publikováno v: Nature reviews. Cardiology. 9(11)
As the PARAMOUNT investigators explain in their report published in the Lancet, “atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) ... act to defend the heart from volume and pressure overload, a protective mechanism recently sh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6998290d12b432e490a7a8b6e77e6b1c
https://pubmed.ncbi.nlm.nih.gov/22932717
Zobrazit plný text záznamu
9
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
Autor: Cesare Gridelli, Paolo Maione, Antonio Rossi
Publikováno v: Reviews on recent clinical trials. 8(1)
The search for new agents and for innovative strategies is warranted in the treatment of advanced non small cell lung cancer (NSCLC) because the outcomes remain unsatisfactory for most patients. Maintenance treatment with either a chemotherapeutic ag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eec09ab8841eb4c21cfa860d56692edf
https://pubmed.ncbi.nlm.nih.gov/23259416
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje